Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer

Immunotherapy is revolutionising cancer treatment and has already emerged as standard treatment for patients with recurrent or metastatic gastric cancer (GC). Recent research has been focused on identifying robust predictive biomarkers for GC treated with immune checkpoint inhibitors (ICIs). The exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Byung Woog, Chau, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440716/
https://www.ncbi.nlm.nih.gov/pubmed/32817133
http://dx.doi.org/10.1136/esmoopen-2020-000791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440716/
https://www.ncbi.nlm.nih.gov/pubmed/32817133
http://dx.doi.org/10.1136/esmoopen-2020-000791

Ejemplares similares